Wen-Hsien Hsu

423 citations
8 papers · 328 indexed · h-index 7
Topics
PI3K/AKT/mTOR signaling in cancer (2 papers)Andrographolide Research and Applications (1 paper)Bone Metabolism and Diseases (1 paper)
Partner nations
TaiwanUnited StatesIndia

In The Last Decade

Wen-Hsien Hsu

8 papers receiving 321 citations

Peers

Wen-Hsien Hsu
Comparison fields: 5 of 73
  • Molecular Biology 152
  • Pharmacology 72
  • Cancer Research 52
  • Complementary and alternative medicine 50
  • Oncology 43
Replace Hasan Slika with:
Hasan Slika United States
Joong‐Seok Woo South Korea
Chia‐Chieh Lin Taiwan
Uteuliyev Yerzhan Sabitaliyevich Kazakhstan
Rıza Serttas Türkiye
Qin Deng China
Ah‐Reum Seong South Korea
Xuan‐Run Wang Macao
Wing Shing Ho Hong Kong
Kwangho Song South Korea
Wen-Hsien Hsu relative to Hasan Slika United States Hasan Slika's profile →
Citations per field
00.5×10×20×30×36×
Hasan Slika · 1×
Citations per year

Countries citing papers authored by Wen-Hsien Hsu

Since Specialization
Citations

This map shows the geographic impact of Wen-Hsien Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wen-Hsien Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wen-Hsien Hsu more than expected).

Fields of papers citing papers by Wen-Hsien Hsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wen-Hsien Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wen-Hsien Hsu. The network helps show where Wen-Hsien Hsu may publish in the future.

Co-authorship network of co-authors of Wen-Hsien Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Wen-Hsien Hsu. A scholar is included among the top collaborators of Wen-Hsien Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wen-Hsien Hsu. Wen-Hsien Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
#WorkIndexed citations
1 72
2 59
3 67
4 3
5 11
6 21
7 41
8 54

About Wen-Hsien Hsu

Wen-Hsien Hsu is a scholar working on Complementary and alternative medicine, Aquatic Science and Pharmacology, having authored 8 papers that have together received 328 indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (2 papers), Andrographolide Research and Applications (1 paper) and Bone Metabolism and Diseases (1 paper). The work is most often cited by research in Complementary and alternative medicine (50 citations), Biochemistry (35 citations) and Pharmacology (72 citations). Wen-Hsien Hsu has collaborated with scholars based in Taiwan, United States and India. Frequent co-authors include Ku‐Chung Chen, Ming-Ting Lee, Chia‐Hsiung Cheng, Joen‐Rong Sheu, Ting‐Lin Yen, Chithan Kandaswami, Cheng‐Wei Lin, George Hsiao, Jie-Jen Lee and Nen‐Chung Chang. Their work appears in journals such as Journal of Ethnopharmacology, Antioxidants and Food & Function.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026